Tech Company Financing Transactions
Ray Therapeutics Funding Round
Ray Therapeutics closed a $6 million Seed funding round on 1/8/2022. Investors included 4BIO Capital and private investors.
Transaction Overview
Company Name
Announced On
1/8/2022
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Seed
Investors
4BIO Capital (Lead Investor) (Dmitry Kuzmin)
Proceeds Purpose
The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis pigmentosa (RP).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3625 Dudley St.
San Diego, CA 92106
USA
San Diego, CA 92106
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Bresge
Chief Operating Officer
Andrew Howard
VP - Manufacturing
Crawford Brown
VP - Regulatory Affairs
Kathrin Schalper
Browse more venture capital transactions:
Prev: 1/8/2022: Verb Data venture capital transaction
Next: 1/11/2022: Swae venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs